Technology:
   U.S. Bioscience, Schering Pact
U.S. Bioscience, a drug company specializing in the
development and commercialization of anti-cancer compounds,
has granted Schering-Plough rights to Hexalen, WR-151327,
PALA, Rogletimide and Ethyol. Hexalen is currently used to
treat ovarian cancer. The other drugs are under development.
Ethyol, still under review by the Food and Drug
Administration, was developed to control the side effects of
chemotherapy in cancer patients.
   Schering-Plough, Madison, N.J., is a leading maker and
marketer of pharmaceuticals and health care products.